Northland Capital Partners Deputy Head of Research, Vadim Alexandre talks to DirectorsTalk about it’s bullish initiation note on Evgen Pharma Plc (LON:EVG). Vadim discusses the attributes liked about Evgen, why the 79p target price and explains why the share price has underperformed since the IPO.
Northland Capital Partners Limited (‘Northland Capital’) is a full-service investment bank based in London focused on growth companies and institutional investors. Our service offering includes Institutional Sales, Equity Research and Corporate Finance. We are focused on small and mid-sized companies that operate in our key sectors.
Northland Capital has assembled a team of highly motivated and experienced professionals that aims to deliver unparalleled service to our clients (institutional and corporate) with value-added research that is complemented by superior execution in Sales and Investment Banking.
Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.